Illustration: Sarah Grillo/Axios

The past 2 years have seen a surge in the number of prescription drugs approved through a special process that was designed to help foster new treatments for rare diseases.

Why it matters: Rapid scientific advances have helped fuel this rise. But the sheer volume of rare-disease approvals is also sparking a debate about whether they're too easy to obtain, or whether they give drugmakers a way to game the system.

How it works: Federal law gives extra market protection and tax credits to "orphan" drugs — those that treat conditions affecting fewer than 200,000 people. The financial incentives are there to help offset the fact that not many people will buy these drugs.

  • The Food and Drug Administration has approved 174 drugs to treat rare diseases under the Trump administration.
  • The approval pathway has been around for 35 years, but about 23% of all orphan approvals have come in the past 2 years.

The rise of personalized medicine, especially through highly complex biologic drugs, has made it easier to target products toward specific rare conditions.

  • Treating a specific subtype of cancer, for example, is one way to win orphan status. One drug, Keytruda, received 6 orphan approvals over the past 2 years for treating different types of skin and immune-system cancers.

Yes, but: Orphan drugs are often very expensive.

  • And in many cases, orphan approvals and the accompanying financial incentives aren't being given to a newly developed drug, but rather for a new use of a product that's already on the market — including drugs that are already blockbusters.
  • In 2017, the average annual cost per patient of the top 100 orphan drugs — excluding blockbusters with additional orphan uses — was $147,308, while the average cost for the top 100 non-orphan drugs was $30,708, according to EvaluatePharma.

Go deeper

Biden clarifies comments on African American and Latino communities

Joe Biden delivering a speech in Delaware in July. Photo: Mark Makela/Getty Images

Joe Biden explained on Twitter Thursday night what he "meant" by earlier comments suggesting that "the African American community is a monolith."

What they're saying: "Unlike the African-American community, with notable exceptions, the Latino community is an incredibly diverse community with incredibly different attitudes about different things," Biden remarked in an interview hosted by the National Association of Hispanic Journalists and the National Association for Black Journalists, Politico reports.

Updated 4 hours ago - Politics & Policy

Ohio Gov. Mike DeWine tests negative for coronavirus after positive result

Photo: Justin Merriman/Getty Images

Ohio Gov. Mike DeWine (R) tested negative for the coronavirus after initially testing positive earlier Thursday, his office announced.

Why it matters: 73-year-old DeWine was set to meet President Trump Thursday on the tarmac at an airport in Cleveland and was tested as part of standard protocol.

Updated 4 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Eniola Odetunde/Axios

  1. Global: Total confirmed cases as of 9:30 p.m. ET: 18,996,008 — Total deaths: 712,476— Total recoveries — 11,478,835Map.
  2. U.S.: Total confirmed cases as of 9:30 p.m. ET: 4,877,115 — Total deaths: 159,990 — Total recoveries: 1,598,624 — Total tests: 59,652,675Map.
  3. Politics: Pelosi rips GOP over stimulus negotiations: "Perhaps you mistook them for somebody who gives a damn" — Ohio Gov. Mike DeWine tests positive.
  4. Public health: Majority of Americans say states reopened too quicklyFauci says task force will examine aerosolized spread Study finds COVID-19 antibodies prevalent in NYC health care workers.
  5. Business: The health care sector imploded in Q2More farmers are declaring bankruptcyJuly's jobs report could be an inflection point for the recovery.
  6. Sports: Where college football's biggest conferences stand on playing.